Viagracom | Pay out

The second important obstacle for the production of the alternatively released reward system work is annually independent that it is necessary, a substantial quantity of rewards to disburse of it the quantity of the innovation and the enterprises must you believe to drugs for neglected diseases 85 that the rewards actually well into the future present is. This is called that the reward grant authorization needs financial support of the governments, and an obligation many years into the future. The reliability requirements are you here those strict for advanced obligations to take delivery, but more similarly, since larger money are requested. During details over the minimum amount, which is required, in order to support an alternatively released reward plan, to have prepared, probably does not seem it that an obligation to disburse $500 at least million annually requested, in order to support a meaningful program. It is possible that an international agreement could help, an obligation to form mechanism. It is useful to see how the alternatively released reward system refers system on the patent to the kind, which rewards are assigned. The patent system mass the value of an innovation by the quantity of profits the pioneer is too able excerpt. Such a measure value, taken directly of the market observations, seems, to suggest that the value of the lives of the very poor people is extreme low. This summary follows directly from the fact, the poor people spends very small money on health care. This, which thinks, led some, to argue that distribution of the money toward to the different kinds from medicine is already efficiently. This is a mistake, since it depends on, whom determines, what is valuable. If the measure of the value is the profitability, which is based on the market prices, then the lives arms are from little importance. But it is that the measure of the value possible used by someone can paying for research be rather different. E.G., international relief organizations, the research in neglected diseases promote believe you obviously that there is another measure value. Their objectives can in the saved lives or other health objectives expressed be designated and it is appropriate for spending the money which is based on such objectives. Indeed generally, the governments, that decide, money apportionable, must from the reason so do from the recognized value basedly on not-financial masses. E.G. a decision to the tax money of a group, an income to another group must make you available to be based on a faith that increase consumption is by the last group from larger importance. The alternatively released reward system follows this basic rule, the value in the pharmaceutical innovation for neglected diseases has little, to do with ability to pay by the consumer but instead of in therapeutic found effects drugThere is really only three possible ways: to determine (the commercial market by the patent system, in order the rewards use 1) for the pioneer, (2) low rewards to the pioneers on therapeutic use, and (3) do not disturb to measure at all. Choice (1) is the patent system, but this works badly for neglected diseases. Advanced obligations to take delivery use choice (2) in a halfhearted kind, since I describe below. Systemof uses the transferable rights at the mental property, down descriptive, choice (3). The key question is in the absence of the meaningful measure of the health effects, is necessary it to create rewards only on commercial success and that is not with an order in agreement to improve the health arms..